Trial Profile
A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Effects of Infliximab (Remicade) on Fat Free Mass in Patients With Moderate to Severe COPD Suffering From Cachexia
Status:
Suspended
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Infliximab (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- 29 Jan 2009 New trial record.